Cancer

Cancer
2024-03-01T00:00:00.000+00:00

MK5684-004

MK5684-004
Prostate Cancer

A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment With One Next-generation Hormonal Agent (NHA)

A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment With One Next-generation Hormonal Agent (NHA)

Trial overview

Disease

Prostate cancer

Topic

OMAHA-2a

Sponsor

MSD

Description

A Phase 3, Randomized, Open-label Study of MK-5684 Versus Alternative Abiraterone Acetate or Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) That Progressed On or After Prior Treatment With One Next-generation Hormonal Agent (NHA)

Study details

For detailed information on this trial, please click here

Trial status

Due to open May 24

Location

Oxford  Windsor :::

Priniciple Investigator

Dr Nicola Dallas

MBChB, MRCP, FRCR

Clinical Oncologist

Windsor +1

Dr Andrew Protheroe

MBBS, FRCP, PhD

Medical oncologist

Milton Keynes +1